DLDandan Liu

Dandan Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dandan Liu has a total of 8 co-authors. Here are the top co-authors by number of shared publications:

  • Chaoyang Zhang

    Department of Ophthalmology, Shanghai General Hospital (Shanghai First People’s Hospital), Shanghai Jiao Tong University School of Medicine, Shanghai, China

    1 shared publication
  • Fang Liu

    Tenth People's Hospital of Tongji University, Shanghai, 200072, China

    1 shared publication
  • Guo-Tong Xu

    Department of Ophthalmology of Tongji Hospital and Laboratory of Clinical and Visual Sciences of Tongji Eye Institute, School of Medicine, Tongji University, Shanghai, China

    1 shared publication
  • Haibin Tian

    Department of Ophthalmology of Tongji Hospital and Laboratory of Clinical and Visual Sciences of Tongji Eye Institute, School of Medicine, Tongji University, Shanghai, China

    1 shared publication
  • Jing Wu

    Tenth People's Hospital of Tongji University

    1 shared publication
  • Jingfa Zhang

    The Primasia International Eye Research Institute, School of Medicine, The Chinese University of Hong Kong, Shenzhen, China

    1 shared publication

Latest Publications

  • Open Access

    Metformin Protects ARPE-19 Cells from Glyoxal-Induced Oxidative Stress

    by Sichang Qu, Chaoyang Zhang, Dandan Liu, Jing Wu, Haibin Tian, Lixia Lu, Guo-Tong Xu, Fang Liu, Jingfa Zhang

    The protective effects and mechanisms of metformin against oxidative stress were evaluated bothin vivoandin vitro. ARPE-19 cells comprised the normal group, the glyoxal-treated group (0.5 mM glyoxal), and the glyoxal+metformin group (0.5 mM glyoxal and 0.1 mM metformin). In thein vitromodel, differences in cell viability, ROS production, NO products, cellular apoptosis, and the expressions of phospho-AMPK alpha, total-AMPK alpha, Sirt1, Nrf2, TXNIP, ZO-1, and Occludin were assessed. In the glyoxal-treated group, cell viability and NO production were decreased, while ROS production and cell apoptosis were increased (p<0.05), compared with the control group. These changes were prevented by metformin treatment. Protein expressions of phospho-AMPK alpha, Sirt1, TXNIP, ZO-1, and Occludin, but not Nrf2, were decreased significantly in the glyoxal-treated group compared to normal controls. Metformin treatment significantly increased the above protein expressions and slightly increased TXNIP expression. Immunofluorescence showed that metformin prevented the glyoxal-induced, disorganized tight junctions in ARPE-19 cells. To confirm metformin's protection, Sprague-Dawley rats were injected intravenously with sodium iodate (SI) to induce oxidative stress in the retinal pigment epithelium (RPE). Metformin was then delivered intraperitoneally or intravitreally. One day and three days after SI and metformin treatments, the RPE-Bruch's membrane-choriocapillaris complex was isolated and immune-stained with ZO-1 antibodies. The morphology of the RPE showed enlarged cellular bodies and disorganized ZO-1 staining in SI-treated rats. Metformin treatment prevented these changes. The results indicated that metformin maintained the barrier functions of RPE cells bothin vivoandin vitro. Metformin exerted its protection against oxidative stress possibly via activating AMPK/Sirt1 and increasing TXNIP. Metformin has been proposed as a candidate drug for age-related macular degeneration (AMD) by both preclinical and clinical studies. The cellular and animal models used in this study might be useful for the interpretation of the molecular mechanisms involved in the drug activity.